Effect of magnesium supplementation on the thickness of the tunica intima media of the carotid arteries in children with chronic kidney disease and hyperphosphatemia

Effect of Magnesium supplementation on cIMT : A Double-blinded Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240719001

Enrollment

Registered

2024-07-19

Start date

2023-11-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The risk of cardiovascular events in children with CKD and hyperphosphatemia can be assessed by measuring the thickness of the intima media of the carotid arteries CKD, hyperphosphatemia, intima media of the carotid arteries

Interventions

give medication with placebo,give medication with magnesium

No Intervention Drug,Placebo Comparator Drug

Placebo,Magnesium

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for this study were pediatric patients aged one month until eighteen years with hyperphosphatemia and CKD with any underlying diagnosis who were newly diagnosed and undergoing inpatient or outpatient therapy at RSUD Dr Soetomo Surabaya

Exclusion criteria

Exclusion criteria: Patients who are undergoing dialysis therapy, both hemodialysis and peritoneal dialysis Patients with blood magnesium levels >2.4 mg/dL Patients who are known to have allergies to magnesium supplementation Patients with blood calcium levels > 10 mg/dL

Design outcomes

Primary

Measure	Time frame
Improvement 3 months echocardiography	—

Secondary

Measure	Time frame
Change of Phosphat Level 3 months Blood examination	—

Countries

Indonesia

Contacts

Public ContactAngga Putu

Universitas Airlangga

putuvirginaas@gmail.com085730288280

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026